Evelo Biosciences, Inc. (EVLO)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -108.46 Million USD | 6.01% |
| 2021 | -115.39 Million USD | -25.59% |
| 2020 | -91.88 Million USD | -6.4% |
| 2019 | -86.35 Million USD | -48.63% |
| 2018 | -58.1 Million USD | -111.05% |
| 2017 | -27.53 Million USD | -111.37% |
| 2016 | -13.02 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q1 | -24.9 Million USD | -18.08% |
| 2023 Q3 | -11.18 Million USD | 42.87% |
| 2023 Q2 | -19.57 Million USD | 21.39% |
| 2022 Q2 | -29.58 Million USD | -2.95% |
| 2022 Q3 | -29.05 Million USD | 1.8% |
| 2022 FY | -108.46 Million USD | 6.01% |
| 2022 Q1 | -28.73 Million USD | -4.28% |
| 2022 Q4 | -21.08 Million USD | 27.42% |
| 2021 Q4 | -27.55 Million USD | 15.75% |
| 2021 Q1 | -27.47 Million USD | 2.58% |
| 2021 Q2 | -27.65 Million USD | -0.67% |
| 2021 FY | -115.39 Million USD | -25.59% |
| 2021 Q3 | -32.71 Million USD | -18.27% |
| 2020 Q3 | -20.18 Million USD | 0.31% |
| 2020 Q2 | -20.24 Million USD | 12.97% |
| 2020 Q4 | -28.19 Million USD | -39.72% |
| 2020 FY | -91.88 Million USD | -6.4% |
| 2020 Q1 | -23.26 Million USD | -2.61% |
| 2019 Q4 | -22.67 Million USD | -5.46% |
| 2019 Q2 | -21.38 Million USD | -2.8% |
| 2019 Q1 | -20.8 Million USD | -30.08% |
| 2019 FY | -86.35 Million USD | -48.63% |
| 2019 Q3 | -21.49 Million USD | -0.51% |
| 2018 Q2 | -15.22 Million USD | -46.07% |
| 2018 FY | -58.1 Million USD | -111.05% |
| 2018 Q4 | -15.99 Million USD | 2.82% |
| 2018 Q3 | -16.45 Million USD | -8.07% |
| 2018 Q1 | -10.42 Million USD | -29.23% |
| 2017 Q1 | -5.2 Million USD | 0.0% |
| 2017 Q2 | -6.21 Million USD | -19.39% |
| 2017 Q3 | -8.03 Million USD | -29.27% |
| 2017 Q4 | -8.06 Million USD | -0.36% |
| 2017 FY | -27.53 Million USD | -111.37% |
| 2016 FY | -13.02 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| America Great Health | -492.64 Thousand USD | -21917.116% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -1039.588% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | -261.638% |
| Biora Therapeutics, Inc. | -67.14 Million USD | -61.545% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | -584.63% |
| Better Therapeutics, Inc. | -38.26 Million USD | -183.482% |
| Calithera Biosciences, Inc. | -42.07 Million USD | -157.798% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | -806.148% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | -220.488% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | -215.134% |
| Evolutionary Genomics, Inc. | -2.01 Million USD | -5284.793% |
| Finch Therapeutics Group, Inc. | -34 Million USD | -218.999% |
| Galera Therapeutics, Inc. | -46.95 Million USD | -131.02% |
| Innovation1 Biotech Inc. | -1.36 Million USD | -7832.361% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | -443.981% |
| Molecular Templates, Inc. | -10.46 Million USD | -936.365% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -671.951% |
| NexImmune, Inc. | -29.19 Million USD | -271.555% |
| Orgenesis Inc. | -53.63 Million USD | -102.226% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | -111.459% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -138928.673% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -571.813% |
| Scopus BioPharma Inc. | -11.71 Million USD | -825.883% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 78.492% |
| Statera Biopharma, Inc. | -98.34 Million USD | -10.293% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -1472.427% |
| Trevena, Inc. | -35.28 Million USD | -207.374% |
| Vaxxinity, Inc. | -58.28 Million USD | -86.096% |
| Vaccinex, Inc. | -22.88 Million USD | -373.961% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -10259.912% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | -113.966% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -1393.402% |